Pamela Stephenson
Corporate Officer/Principal chez DISC MEDICINE, INC.
Fortune : 972 382 $ au 30/04/2024
Profil
Pamela Stephenson is currently the Chief Commercial Officer at Disc Medicine, Inc. Her former positions include being an Independent Director at Zynerba Pharmaceuticals, Inc. from 2019 to 2023, and Vice President-Global Market Access & Value at Vertex Pharmaceuticals, Inc. from 2008 to 2019.
She also served as the Chief Commercial Officer at Albireo Pharma, Inc. Ms. Stephenson received her undergraduate degree from Brown University and her graduate degree from Boston University School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DISC MEDICINE, INC.
0,15% | 26/02/2024 | 36 666 ( 0,15% ) | 972 382 $ | 30/04/2024 |
Postes actifs de Pamela Stephenson
| Sociétés | Poste | Début |
|---|---|---|
| DISC MEDICINE, INC. | Corporate Officer/Principal | 26/02/2024 |
Anciens postes connus de Pamela Stephenson
| Sociétés | Poste | Fin |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 10/10/2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/03/2019 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
Formation de Pamela Stephenson
| Brown University | Undergraduate Degree |
| Boston University School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| DISC MEDICINE, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
